Harvard Bioscience (HBIO) 10-Q5 Nov 152015 Q3 Quarterly reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2015	Oct. 30, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Document period end date	Sep. 30, 2015
Amendment flag	false
Document Period Focus	Q3
Document Fiscal Year Focus	2,015
Current fiscal year end date	--12-31
Entity central index key	1,123,494
Entity current reporting status	Yes
Entity filer category	Accelerated Filer
Entity registrant name	HARVARD BIOSCIENCE INC
Entity voluntary filers	No
Entity well known seasoned issuer	No
Entity common stock shares outstanding		33,944,207
Trading Symbol	HBIO

Statements of Financial Positio

Statements of Financial Position - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current Assets:
Cash and cash equivalents	$ 6,090	$ 14,134
Accounts receivable, net of allowance for doubtful accounts of $330 and $328, respectively	15,590	16,141
Inventories	23,011	20,531
Deferred income tax assets - current	2,563	1,515
Other receivables and other assets	5,070	4,742
Total current assets	52,324	57,063
Property, plant and equipment, net	5,934	5,190
Deferred income tax assets - non-current	11,046	11,056
Amortizable intangible assets, net	21,813	21,153
Goodwill	40,858	39,822
Other indefinite lived intangible assets	1,231	1,252
Other assets	349	380
Total Assets	133,555	135,916
Current liabilities:
Current portion, long-term debt	5,000	5,000
Accounts payable	6,322	6,294
Deferred revenue	795	655
Accrued income taxes payable	214	554
Deferred income tax liabilities - current	244	121
Accrued expenses	3,840	4,452
Other liabilities - current	855	1,023
Total current liabilities	17,270	18,099
Long-term debt	15,150	16,450
Deferred income tax liabilities - non-current	2,256	1,325
Other liabilities- non current	4,593	4,574
Total liabilities	39,269	40,448
Stockholders Equity Abstract
Preferred stock, par value $0.01 per share, 5,000,000 shares authorized	0	0
Common stock, par value $0.01 per share, 80,000,000 shares authorized; 41,689,714 and 40,308,763 shares issued and 33,944,207 and 32,563,256 shares outstanding, respectively	416	397
Additional paid-in-capital	210,655	206,656
Accumulated deficit	(94,583)	(92,684)
Accumulated other comprehensive loss	(11,534)	(8,233)
Treasury stock at cost, 7,745,507 common shares	(10,668)	(10,668)
Total stockholders' equity	94,286	95,468
Total liabilities and stockholders' equity	$ 133,555	$ 135,916

Statements of Financial Positi3

Statements of Financial Position (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
CONSOLIDATED BALANCE SHEETS
Allowance for doubtful accounts	$ 330	$ 328
Preferred Stock Par value	$ 0.01	$ 0.01
Preferred Stock - Shares Authorized	5,000,000	5,000,000
Common stock par value	$ 0.01	$ 0.01
Common Stock- Shares Authorized	80,000,000	80,000,000
Common Stock- Shares Issued	41,689,714	40,308,763
Common Stock- Shares Outstanding	33,944,207	32,563,256
Treasury Stock common shares	7,745,507	7,745,507

Statements of Operations

Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Statements of Operations - USD ($) $ in Thousands	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
CONSOLIDATED STATEMENTS OF OPERATIONS
Revenues	$ 25,731	$ 25,448	$ 80,294	$ 78,299
Cost of revenues (exclusive of items shown separately below)	14,005	14,006	44,495	42,818
Gross profit	11,726	11,442	35,799	35,481
Sales and marketing expenses	5,028	4,113	15,355	13,102
General and administrative expenses	5,005	4,130	14,758	12,378
Research and development expenses	1,426	1,059	4,888	3,316
Restructuring charges (credits)	376	97	487	349
Amortization of intangible assets	666	618	2,137	1,839
Total Operating Expenses	12,501	10,017	37,625	30,984
Operating income	(775)	1,425	(1,826)	4,497
Other (expense) income:
Foreign exchange	70	0	159	(148)
Interest expense	(204)	(239)	(641)	(752)
Interest income	1	19	5	45
Other income (expense), net	(188)	(249)	(984)	(397)
Other expense, net	(321)	(469)	(1,461)	(1,252)
Income from continuing operations before income taxes	(1,096)	956	(3,287)	3,245
Total Income Tax Expense	(249)	323	(1,388)	871
Net income (loss)	$ (847)	$ 633	$ (1,899)	$ 2,374
Earnings (loss) per share:
Basic earnings per common share	$ (0.02)	$ 0.02	$ (0.06)	$ 0.07
Diluted Earnings Per Common Share	$ (0.02)	$ 0.02	$ (0.06)	$ 0.07
Weighted average common shares:
Basic	33,933,327	32,341,586	33,473,958	32,079,744
Diluted	33,933,327	33,414,857	33,473,958	33,097,012
Consolidated Statements of Comprehensive Income [Abstract]
Foreign currency translation adjustments	$ (526)	$ (3,168)	$ (3,263)	$ (2,584)
Other Comprehensive Income Derivatives Qualifying As Hedges Net Of Tax Period Increase Decrease [Abstract]
Loss on derivative instruments designated and qualifying as cash flow hedges	(39)	23	(110)	(57)
Amounts reclassified from accumulated other comprehensive income to net income	22	31	72	100
Unrealized losses on pension benefit obligation, net of tax	0	0	0	(484)
Total Comprehensive Income (Loss), Net of Tax, total	$ (1,390)	$ (2,481)	$ (5,200)	$ (651)

Statements of Cash Flows

Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
Statements of Cash Flows - USD ($) $ in Thousands	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities:
Net income (loss)	$ (1,899)	$ 2,374
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation expense	2,049	1,534
Depreciation	1,157	913
(Gain) loss on sales of fixed assets	25	8
Non cash restructuring charge	(79)	(120)
Amortization Of Catalog Costs	8	37
Provision for allowance for doubtful accounts	3	(34)
Amortization of intangible assets	2,137	1,839
Amortization of deferred financing costs	58	46
Deferrred Income Taxes	(1,024)	259
Changes in operating assets and liabilities:
(Increase) decrease in accounts receivable	754	(557)
Increase in inventories	(1,310)	(2,649)
Increase in other receivables and other assets	(407)	(466)
Increase in trade accounts payable	35	446
(Decrease) increase in accrued income taxes	(362)	(107)
Increase in accrued expenses	(2,046)	(486)
(Decrease) increase in deferred revenue	158	(38)
Increase (decrease) in other liabilities	(316)	89
Net cash provided by operating activities	(1,059)	3,088
Cash flows (used in) provided by investing activities:
Additions to property, plant and equipment	(2,298)	(1,224)
Proceeds from sales of property, plant and equipment	6	76
Acquisitions, net of cash acquired	(4,545)	0
Net cash used in investing activities	(6,837)	(1,148)
Cash flows provided by (used in) financing activities:
Repayments of debt	(6,100)	(3,750)
Net proceeds from issuance of debt	4,800	2,200
Payments of debt issuance costs	(32)	0
Net proceeds from issuance of common stock	1,953	1,415
Net cash (used in) provided by financing activities	621	(135)
Effect of exchange rate changes on cash	(769)	(842)
Increase in cash and cash equivalents	(8,044)	963
Cash and cash equivalents at the begining of period	14,134	25,771
Cash and cash equivalents at the end of period	6,090	26,734
Supplemental disclosures of cash flow information [Abstract]
Cash paid for interest	625	757
Cash paid for income taxes, net of refunds	$ 625	$ 451

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2015
Basis of Presentation and Summary of Significant Accounting Policies Disclosure [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies Disclosure [Text Block]	HARVARD BIOSCIENCE, INC. NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS 1. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation The unaudited consolidated financial statements of Harvard Bioscience, Inc. and its wholly-owned subsidiaries (collectively, “Harvard Bioscience” or the “Company”) as of September 30, 2015 and for the three and nine months ended September 30, 2015 and 2014 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been cond ensed or omitted pursuant to such rules and regulations. The December 31, 2014 consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. However, the Company believes tha t the disclosures are adequate to make the information presented not misleading. These unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annu al Report on Form 10-K for the fiscal year ended December 31, 2014 , which was filed with the SEC on March 12, 2015. In the opinion of management, all adjustments, which include normal recurring adjustments necessary to present a fair statement o f financial position as of September 30, 2015 , results of operations and comprehensive loss for the three and nine months ended September 30, 2015 and 2014 and cash flows for the nine months ended September 30, 2015 and 2014 , as applicable, have been made. The results of operations for the three and nine months ended September 30, 2015 are not necessarily indicative of the operating results for the full fiscal year or any future periods. Summary of Significant Accounting P olicies The accounting policies underlying the accompanying unaudited consolidated financial statements are those set forth in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 , which was filed with the SEC on March 12, 2015.

Recently Issued Accounting Pron

Recently Issued Accounting Pronouncements	9 Months Ended
Recently Issued Accounting Pronouncements	Sep. 30, 2015
Recently Issued Accounting Pronouncements [Abstract]
Recently Issued Accounting Pronouncements Disclosure [Text Block]	2 . Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, “Revenue from Contracts with Customers,” a new accounting standard that provides for a comprehensive model to use in the accounting for revenue arising from contracts with customers that will replace most existing revenue recognition guidance in U.S. GAAP. Under this standard, revenue will be re cognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. At its July 2015 meeting, the FASB agreed to defer the mandatory effective date of ASU 2014-09 one year. Under the one year deferral, the standard will take effect in 2018 for calendar year-end public entities. The Company is assessing the new standard and has not yet determined the impact to the consolida ted financial statements. In April 2015, the FASB issued ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs . The update requires debt issuance costs related to a recognized debt liabili ty to be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability, instead of being presented as an asset. Debt disclosures will include the face amount of the debt liability and the effective interest rat e. The update requires retrospective application and represents a change in accounting principle. The update is effective for fiscal years beginning after December 15, 2015. Early adoption is permitted for financial statements that have not been previousl y issued. The Company is evaluating the impact of ASU 2015-03 on its consolidated financial statements and the possibility of early adoption by the Company. In July 2015, the FASB issued ASU 2015-11, Simplifying Measurement of Inventory . The update requir es measurement of most inventory “at the lower of cost and net realizable value”, and applies to all entities that recognize inventory within the scope of ASC 330, except for inventory measured under the last-in, first-out (LIFO) method or the retail inven tory method (RIM). ASU 2015-11 requires prospective application and represents a change in accounting principle. The update is effective for fiscal years beginning after December 15, 2016. Early adoption is permitted for financial statements that have not been previously issued. The Company is evaluating the impact of ASU 2015-11 on its consolidated financial statements and the possibility of early adoption by the Company. In September 2015, the FASB issued ASU 2015-16, Simplifying the Accounting for Meas urement-Period Adjustments . The update eliminates the requirement to retrospectively adjust financial statements for measurement-period adjustments that occur in periods after a business combination. Under the update, measurement-period adjustments are to be calculated as if they were known at the acquisition date, but are recognized in the reporting period in which they are determined. Additional disclosures are required about the impact on current-period earnings. ASU 2015-16 requires prospective applicat ion to adjustments of provisional amounts that occur after the effective date. The update is effective for fiscal years beginning after December 15, 2016. Early adoption is permitted for financial statements that have not been previously issued. The Compa ny is evaluating the impact of ASU 2015-16 on its consolidated financial statements and the possibility of early adoption by the Company.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	9 Months Ended
Accumulated Other Comprehensive Income	Sep. 30, 2015
Accumulated Other Comprehensive Income [Abstract]
Accumulated Other Comprehensive Income Disclosure [Text Block]	3 . Accumulated Other Comprehensive Loss Changes in each component of accumulated other comprehensive loss , net of tax are as follows: Foreign currency Derivatives translation qualifying as Defined benefit (in thousands) adjustments hedges pension plans Total Balance at December 31, 2014 $ (4,658) $ (18) $ (3,557) $ (8,233) Other comprehensive loss before reclassifications (3,263) (110) - (3,373) Amounts reclassified from AOCI - 72 - 72 Other comprehensive loss (3,263) (38) - (3,301) Balance at September 30, 2015 $ (7,921) $ (56) $ (3,557) $ (11,534)

Acquisitions

Acquisitions	9 Months Ended
Acquisitions	Sep. 30, 2015
Acquisition Disclosure [Abstract]
Acquisitions Disclosure [Text Block]	4. Acquisitions The Company completed one acquisition during the nine months ended September 30, 2015 . HEKA Elektronik On January 8, 2015, the Company, through its wholly-owned Ealing Scientific Limited and Multi Channel Systems MCS GmbH (“MCS”) subsidiaries, acquired all of the issued and outstanding shares of HEKA Elektronik (“HEKA”) for approximately $5.9 million, or $4.5 million, net of cash acquired. Included in the acquisition of HEKA are: HEKA Electronik Dr. Schulze GmbH, based in Lambrecht , Germany (“HEKA Germany”); HEKA Electronics Incorporated, based in Chester, Nova Scotia, Canada (“HEKA Canada”); and HEKA Instruments Incorporated, based in Bellmore, New York. The Company funded the acquisition from its existing cash ba lances. HEKA is a developer, manufacturer and marketer of sophisticated electrophysiology instrumentation and software for biomedical and industrial research applications. This acquisition is complementary to the electrophysiology line currently offered by the Company’s wholly-owned Warner Instruments and MCS subsidiaries. The aggregate purchase price for this acquisition was preliminarily allocated to tangible and intangible assets acquired as follows: (in thousands) Tangible assets $ 4,165 Liabilities assumed (2,819) Net assets 1,346 Goodwill and intangible assets: Goodwill 2,061 Trade name 774 Customer relationships 1,627 Developed technology 1,338 Non-compete agreements 27 Deferred tax liabilities (1,245) Total goodwill and intangible assets, net of tax 4,582 Acquisition purchase price $ 5,928 The estimated purchase price allocation is preliminary and subject to revision. A valuation of the assets acquired and liabilities assumed is being conducted and the final allocation will be made when completed. Goodwill recorded as a result of the acquisition of HEKA is not deductible for tax purposes. The results of operations for HEKA have been included in the Company’s consolidated financial statements from the date of acquisition and are not material. The following consolidated pro forma info rmation is based on the assumption that the acquisition of HEKA occurred on January 1, 2014. Accordingly, the historical results have been adjusted to reflect amortization expense that would have been recognized on such a pro forma basis. The pro forma information is presented for comparative purposes only and is not necessarily indicative of the financial position or results of operations which would have been reported had we completed the acquisition during these periods or which might be report ed in the future. Three Months Ended Nine Months Ended September 30, 2014 September 30, 2014 (in thousands) Pro Forma Revenues $ 26,829 $ 82,441 Net income 707 2,597 The Company completed two acquisitions during 2014. Multi Channel Systems MCS GmbH On October 1, 2014, the Company, through its wholly-owned Biochrom Limited subsidiary, acquired all of the issued and outstanding shares of Multi Channel Systems MCS GmbH , which has its principal offices in Germany, for approximately $11.2 million, including a working capital adjustment. The Company funded the acquisition from its existing cash balances. MCS is a developer, manufacturer and marke ter of in vitro and in vivo electrophysiology instrumentation for extracellular recording and stimulation. This acquisition is complementary to the in vitro electrophysiology line currently offered by the Company’s wholly-owned Warner Instruments subsidiar y. The aggregate purchase price for this acquisition was allocated to tangible and intangible assets acquired as follows: (in thousands) Tangible assets $ 5,442 Liabilities assumed (1,207) Net assets 4,235 Goodwill and intangible assets: Goodwill 3,745 Trade name 1,008 Customer relationships 1,204 Developed technology 2,452 Non-compete agreements 148 Deferred tax liabilities (1,603) Total goodwill and intangible assets, net of tax 6,954 Acquisition purchase price $ 11,189 Goodwill recorded as a result of the acquisition of MCS is not deductible for tax purposes. The results of operations for MCS have been included in the Company’s consolidated financial statements from the date of acquisition and are not material. The following consolidated pro forma information is based on the assumption that the acquisition of MCS occurred on January 1, 2014. Accordingly, the historical results have been adjusted to reflect amortization expense that would have been recognized on such a pro forma basis. The pro forma information is presented for comparative purposes only and is not necessarily indicative of the financial position or results of operations which would have been reported had we completed the acquisition during th ese periods or which might be reported in the future. Three Months Ended Nine Months Ended September 30, 2014 September 30, 2014 (in thousands) Pro Forma Revenues $ 27,209 $ 83,702 Net income 713 2,619 Triangle BioSystems , Inc. On October 1, 2014, the Company acquired all of the issued and outstanding shares of Triangle BioSystems , Inc. (“TBSI”), which has it s principal offices in North Carolina, for approximately $2.2 million, including a working capital adjustment. The Company funded the acquisition from borrowings under its credit facility. TBSI is a developer, manufacturer and marketer of wireless neural interface equipment to aid in vivo neuroscience research, especially in the fields of electrophysiology, psychology, neurology and pharmacology. This acquisition is complementary to the behavioral neuroscience lines currently offered by the Company’s whol ly-owned Panlab and Coulbourn subsidiaries. The aggregate purchase price for this acquisition was allocated to tangible and intangible assets acquired as follows: (in thousands) Tangible assets $ 1,278 Liabilities assumed (530) Net assets 748 Goodwill and intangible assets: Goodwill 946 Trade name 143 Customer relationships 308 Developed technology 363 Non-compete agreements 30 Deferred tax liabilities (325) Total goodwill and intangible assets, net of tax 1,465 Acquisition purchase price $ 2,213 The results of operations for TBSI have been included in the Company’s consolidated financial statements from the date of acquisition and are not material. The Company considers this acquisition immaterial for the purposes of proforma financial statement disclosures. Goodwill recorded as a result of the acquisition of TBSI is not deductible for tax purposes. Direct acquisition costs recorded in other expense, net in the Company’s consolidated statements of operations were $ 0.2 million and $ 0.9 million for the three and nine months ended September 30, 2015 , respectively, and $ 0.3 million and $ 0.4 million for the three and nine months ended September 30, 2014 , respectively.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	9 Months Ended
Goodwill and Other Intangible Assets	Sep. 30, 2015
Goodwill And Other Intangible Assets Disclosure [Abstract]
Goodwill And Other Intangible Assets Disclosure [Text Block]	5. Goodwill and Other Intangible Assets Intangible assets consist of the following: Weighted Average September 30, 2015 December 31, 2014 Life (a) (in thousands) Amortizable intangible assets: Gross Accumulated Amortization Gross Accumulated Amortization Existing technology $ 16,287 $ (11,620) $ 15,538 $ (11,198) 7.5 Years Trade names 7,685 (2,954) 7,114 (2,557) 9.2 Years Distribution agreements/customer relationships 23,818 (11,568) 22,730 (10,681) 10.2 Years Patents 250 (85) 256 (49) 3.4 Years Total amortizable intangible assets 48,040 $ (26,227) 45,638 $ (24,485) Indefinite-lived intangible assets: Goodwill 40,858 39,822 Other indefinite-lived intangible assets 1,231 1,252 Total goodwill and other indefinite-lived intangible assets 42,089 41,074 Total intangible assets $ 90,129 $ 86,712 (a) Weighted average life as of September 30, 2015. The change in the carrying amount of goodwill for the nine months ended September 30, 2015 is as follows: (in thousands) Balance at December 31, 2014 $ 39,822 Goodwill arising from business combinations 2,061 Effect of change in currency translation (1,025) Balance at September 30, 2015 $ 40,858 Intangible asset amortization expense was $ 0.7 million and $ 0.6 million for the three months ended September 30, 2015 and 2014 , respectively. Intangible asset amortization expense was $ 2.1 million and $ 1.8 million for the nine months ended September 30, 2015 and 2014 , respectively. Amortization expense of existing amortizable intangible assets is currently estimated to be $ 2.8 million for the year ending December 31, 2015 , $ 2.8 million for the year ending December 31, 2016 , $ 2.5 million for the year ending December 31, 2017 , $ 2.3 million for the year ending December 31, 2018 and $ 2.2 million for the year ending December 31, 2019 .

Inventories

Inventories	9 Months Ended
Inventories	Sep. 30, 2015
Inventories Disclosure [Abstract]
Inventories Disclosure [Text Block]	6. Inventories Inventories consist of the following: September 30, December 31, 2015 2014 (in thousands) Finished goods $ 10,169 $ 10,138 Work in process 949 946 Raw materials 11,893 9,447 Total $ 23,011 $ 20,531

Property, Plant and Equipment

Property, Plant and Equipment	9 Months Ended
Property, Plant and Equipment	Sep. 30, 2015
Property, Plant and Equipment Disclosure [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	7 . Property , Plant and Equipment Property, plant and equipment consist of the following: September 30, December 31, 2015 2014 (in thousands) Land, buildings and leasehold improvements $ 2,635 $ 2,595 Machinery and equipment 10,129 10,102 Computer equipment and software 7,356 6,322 Furniture and fixtures 1,353 1,125 Automobiles 106 56 21,579 20,200 Less: accumulated depreciation (15,645) (15,010) Property, plant and equipment, net $ 5,934 $ 5,190

Restructuring and Other Exit Co

Restructuring and Other Exit Costs	9 Months Ended
Restructuring and Other Exit Costs	Sep. 30, 2015
Restructuring and Related Activities [Abstract]
Restructuring And Other Exit Costs Disclosure [Text Block]	8 . Restructuring and Other Exit Costs Q2 201 5 Restructuring Plan During the second quarter of 201 5 , management of Harvard Bioscience initiated a plan to consolidate the manufacturing operations of HEKA Canad a to HEKA Germa n y in order to create organizational efficiencies . No further charges are expected to be incurred on this matter. At September 30, 2015 , the Company has no remaining liability related to this plan on its balance sheet. Act ivity and liability balances related to these charges were as follows: Severance Costs (in thousands) Restructuring charges $ 14 Cash payments (14) Restructuring balance at September 30, 2015 $ - Q1 201 5 Restructuring Plan During the first quarter of 201 5 , management of Harvard Bioscience initiated a plan to relocate certain manufacturing operations in order to create organizational efficiencies and reduce op erating expenses. The 2015 restructuring plan included plans to consolidate the manufacturing operations of its Coulbourn subsidiary to its headquarters in Holliston, MA. During the nine months ended September 30, 2015 , t he Company recorded restructuring charges of app roximate ly $ 0.2 million . Payments related to this plan are expected to be made through the end of 2015 . Activity and liability balances related to these charges were as follows: Severance Costs Other Total (in thousands) Restructuring charges $ 126 46 $ 172 Non-cash reversal of restructuring charges (6) - (6) Cash payments (59) (32) (91) Restructuring balance at September 30, 2015 $ 61 14 $ 75 201 4 Restructuring Plan During the fourth quarter of 201 4 , management of Harvard Bioscience initiated a plan to relocate certain distribution and manufacturing operations in order to create organizational efficiencies and reduce op erating expenses. The 2014 restructuring plan included plans to relocate the distribution operations of the Company’s Denville subsidiary from New Jersey to North Carolina, as well as consolidating the manufacturing operations of its Biochrom subsidiary to its headquarters in H olliston, MA. Payments related to this plan are expected to be made through the end of 2015 . Activity and liability balances related to these charges were as follows: Severance Costs Other Total (in thousands) Restructuring balance at December 31, 2014 $ 626 $ - $ 626 Restructuring charges 87 293 380 Non-cash reversal of restructuring charges (73) - (73) Cash payments (577) (263) (840) Effect of change in currency translation (8) - (8) Restructuring balance at September 30, 2015 $ 55 $ 30 $ 85 2013 Restructuring Plan During the fourth quarter of 2013, the management of Harvard Bioscience initiated a plan to realign global operations to improve organizational efficiencies and reduce operating exp enses throughout the Company. The plan included an approximately 13% reduction in the workforce, as well as the elimination of the position of Chief Operating Officer. No further charges are expected to be incurred on this matter. At December 31, 2014 and September 30, 2015 , the Company had no remaining liability related to this plan on its balance sheet. Activity and liability balances related to these charges in 2014 were as follows: Severance and Fixed Asset Related Costs Write Offs Other Total (in thousands) Restructuring balance at December 31, 2013 $ 1,434 $ - $ - $ 1,434 Restructuring charges 199 13 257 469 Non-cash reversal of restructuring charges (117) (13) - (130) Cash payments (1,447) - (234) (1,681) Restructuring balance at September 30, 2014 $ 69 $ - $ 23 $ 92 2012 Restructuring Plan During 2012, the management of Harvard Bioscience initiated a plan to reduce operating expenses at one of its foreign subsidiaries. No further charges are expected to be incurred on this matter. At December 31, 2014 and September 30, 2015 , the Company had no remaining liability related to this plan on its balance sheet. Activity and liability balances related to these charges in 2014 were as follows: Severance and Related Costs (in thousands) Restructuring balance at December 31, 2013 $ 3 Non-cash reversal of restructuring charges (3) Restructuring balance at September 30, 2014 $ - Aggregate net restructuring charges for the three and nine months ended September 30, 2015 and 2014 were as follows: Three Months Ended Nine Months Ended September 30, September 30, 2015 2014 2015 2014 (in thousands) Restructuring charges $ 376 $ 97 $ 487 $ 349

Related Party Transactions

Related Party Transactions	9 Months Ended
Related Party Transactions	Sep. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	9 . Related Party Transactions As part of the acquisitions of MCS and TBSI, the Company signed lease agreements with the former owners of the acquired companies. The principals of such former owners were employees of the C om pany as of September 30, 2015 . Pursuant to the lease agreement , the Company incurred rent expense of approximately $ 59,000 and $ 172,000 to the former owners of MCS for the three and nine months ended September 30, 2015 , respectively . Pursuant to the lease agreement , the Company incurred rent expense of approximately $ 11,000 and $ 32,000 to the former owner of TBSI for the three and nine months ended September 30, 2015 , respectively .

Warranties

Warranties	9 Months Ended
Warranties	Sep. 30, 2015
Warranties Disclosure [Abstract]
Warranties Disclosure [Text Block]	10 . Warranties Warranties are estimated and accrued at the time revenues are recorded. A rollforward of the Company’s product warranty accrual is as follows: Beginning Additions/ Ending Balance Payments (Credits) Balance (in thousands) Year ended December 31, 2014 $ 305 (102) 49 $ 252 Nine months ended September 30, 2015 $ 252 (73) (33) $ 146

Employee Benefit Plans

Employee Benefit Plans	9 Months Ended
Employee Benefit Plans	Sep. 30, 2015
Employee Benefit Plans Disclosure [Abstract]
Employee Benefit Plans Disclosure [Text Block]	11 . Employee Benefit Plans Certain of the Company’s subs idiaries in the United Kingdom, or UK, Harvard Apparatus Limited and Biochrom Limited, maintain contributory, defined benefit or defined contribution pension plans for substantially all of their employees. As of the quarter ended September 30, 2014 , the principal employer of the Harvard Apparatus Limited pension plan was changed from Harvard Apparatus Limited to Biochrom Limited. As of the quarter ended June 30, 2014 , these defined benefit pension plans were closed to new employees, as well as closed to the future accrual of benefits for existing employees. The components of the Company’s defined benefit pension expense were as follows: Three Months Ended Nine Months Ended September 30, September 30, 2015 2014 2015 2014 (in thousands) Components of net periodic benefit cost: Interest cost 175 200 542 649 Expected return on plan assets (165) (147) (510) (478) Net amortization loss 75 40 231 131 Net periodic benefit cost $ 85 $ 93 $ 263 $ 302 For the three months ended September 30, 2015 and 2014 , the Company contributed $ 0.2 million , for both periods , to its defined benefit pension plans. For the nine months ended September 30, 2015 and 2014 , the Company contributed $ 0.6 million , for both periods , to its defined benefit pension plans. The Company expects to contribute approximately $0. 2 million to its defined benefit pension plans during the remainder of 2015 . During the nine months ended September 30, 2014 the Company wrote down its Level 3 investment in a longevity fund by an additional $0.6 million, which reduced its value to $0. The impact on accumulated other comprehensive loss was $0.5 million, net of tax. The longevity fun d invests in a portfolio of physical life insurance settlements that had been historically valued using the net asset values provided by the fund. Since June 2011, the fund has been closed to all activity. The write down during the nine months ended September 30, 2014 was due, in part, to communication from the longevity fund regarding its continued illiquidity and inactivity. There has been no change in the status of the longevity fund since 2014. As of September 30, 2015 and December 31, 2014 , the Company had an underfunded pension liability of approxima tely $4. 5 million and $4.4 million, respectively, included in the other liabilities – non-current line item in the consolidated balance sheets .

Leases

Leases	9 Months Ended
Leases	Sep. 30, 2015
Leases Disclosure [Abstract]
Leases Disclosure [Text Block]	12 . Leases The Company has noncancelable operating leases for office and warehouse space expiring at various dates through 2020 and thereafter. Rent expense, which is recorded on a straight-line basis, is estimated to be $ 2.2 million for the year ended December 31, 2015 . Rent expense was approximately $ 0.6 million and $ 1.8 million for the three and nine months ended September 30, 2015 , respectively. Rent expense was approximately $ 0.3 million and $ 1.1 million for the three and nine months ended September 30, 2014 , respectively. Future minimum lease payments for operating leases, with initial or remaining terms in excess of one year at September 30, 2015 , are as follows: Operating Leases (in thousands) 2016 $ 1,803 2017 1,705 2018 1,688 2019 1,490 2020 1,490 Thereafter 4,508 Net minimum lease payments $ 12,684

Capital Stock

Capital Stock	9 Months Ended
Capital Stock	Sep. 30, 2015
Capital Stock Disclosure [Abstract]
Capital Stock Disclosure [Text Block]	13 . Capital Stock Common Stock On February 5, 2008, the Company’s Board of Directors adopted a Shareholder Rights Plan and declared a dividend distribution of one preferred stock purchase right for each outstanding share of the Company’s common stock to shareholders of record as of the close of business on February 6, 2 008. Initially, these rights will not be exercisable and will trade with the shares of the Company’s common stock. Under the Shareholder Rights Plan, the rights generally will become exercisable if a person becomes an “acquiring person” by acquiring 20% or more of the common stock of the Company or if a person commences a tender offer that could result in that person owning 20% or more of the common stock of the Company. If a person becomes an acquiring person, each holder of a right (other than the acquiri ng person) would be entitled to purchase, at the then-current exercise price, such number of shares of preferred stock which are equivalent to shares of the Company’s common stock having a value of twice the exercise price of the right. If the Company is a cquired in a merger or other business combination transaction after any such event, each holder of a right would then be entitled to purchase, at the then-current exercise price, shares of the acquiring company’s common stock having a value of twice the ex ercise price of the right. Preferred Stock The Company’s Board of Directors has the authority to issue up to 5.0 million shares of preferred stock and to determine the price privileges and other terms of the shares. The Board of Directors may exercise th is authority without any further approval of stockholders. As of September 30, 2015 , the Company had no preferred stock issued or outstanding . Employee Stock Purchase Plan (as amended, the “ESPP”) In 2000, the Company approved the ESPP . Under thi s ESPP , participating employees can authorize the Company to withhold a portion of their base pay during consecutive six-month payment periods for the purchase of shares of the Company’s common stock. At the conclusion of the period, participating employee s can purchase shares of the Company’s common stock at 85% of the lower of the fair market value of the Company’s common stock at the beginning or end of the period. Shares are iss ued under the ESPP for the six-month periods ending June 30 and December 31. Under this plan, 750,000 shares of common stock are authorized for issuance of which 611,369 shares were issue d as of September 30, 2015 . During the nine months ended September 30, 2015 and 2014 , the Company issued 26,181 shares and 31,116 shares, respectively, of the Company’s common stock under the ESPP. There were no shares issued under the ESPP during the three months ended September 30, 2015 and 2014 . Third Amended and Restated 2000 Stock Option and Incentive Plan (as amended, the “Third A&R Plan”) The Second Amendment to the Third A&R Plan (the “Amendment”) was adopted by the Board of Directors on April 3, 2015. Such Amendment was approved by the stockholders at the Company’s 2015 Annual Meeting. Pursuant to the Amendment, the aggregate number of shares authorized for issuance under the Third A&R Plan was increased by 2,500,000 shares to 17,508,929. Restricted Stock Units with a Market Condition (the “Market Condition RSU’s) On August 3, 2015, the Compensation Committee of the Board of Directors of the Company approved and granted deferred stock awards of Market Condition RSU’s to members of the Company’s management team under the Third A&R Plan. The vesting of these Market Condition RSU’s is cliff-based and linked to the achievement of a relative total shareholder return of the Company’s common stock from August 3, 2015 to the earlier of ( i ) August 3, 2018 or (ii) upon a change of con trol (measured relative to the Russell 3000 index and based on the 20-day trading average price before each such date). As of September 30, 2015 , t he target number of these restricted stock units that may be earned is 196,782 shares; the maximum amount is 150% of the target number. Stock-Based Payment Awards The Company accounts for stock-based payment awards in accordance with the provisions of FASB ASC 718, which requires it to recognize compensation expense for all stock-based payment awards made to employees and directors incl uding stock options, restricted stock units, Market Condition RSU’s and employee stock purchases related to the ESPP. Stock option and restricted stock unit activity under the Company’s Third A&R Plan for the nine months ended September 30, 2015 was as follows: Stock Options Restricted Stock Units Market Condition RSU's Weighted Stock Average Restricted Market Options Exercise Stock Units Grant Date Condition RSU's Grant Date Outstanding Price Outstanding Fair Value Outstanding Fair Value Balance at December 31, 2014 6,263,112 $ 3.42 306,397 $ 4.30 - $ - Granted 868,000 5.51 254,685 5.56 196,785 4.81 Exercised (1,739,134) 3.04 - - - - Vested (RSUs) - - (237,188) - - - Cancelled / forfeited (272,121) 3.98 - - - - Balance at September 30, 2015 5,119,857 $ 3.87 323,894 $ 5.30 196,785 $ 4.81 The weighted average fair value of the options granted under the Third A&R Plan during the three months ended September 30, 2015 and 2014 was $ 2.14 and $ 2.64 , respectively. The weighted average fair value of the options granted under the Third A&R Plan during the nine months ended September 30, 2015 and 2014 was $ 2.21 and $ 2.20 , respectively . The following assumptions were used to estimate the fair value , using the Black-Scholes option pricing model, of stock options granted during the three and nine months ended September 30, 2015 and 2014 : Three Months Ended Nine Months Ended September 30, September 30, 2015 2014 2015 2014 Volatility 39.47 % 56.96 % 41.07 % 56.83 % Risk-free interest rate 1.76 % 1.90 % 1.72 % 1.79 % Expected holding period (in years) 5.25 years 5.93 years 5.52 years 5.75 years Dividend yield - % - % - % - % The weighted average fair value of the Market Condition RSU’s granted under the Third A&R Plan during the three months ended September 30, 2015 was $ 4.81 . The following assumptions were used to estimate the fair value , using a Monte-Carlo valuation simulation, of the Market Condition RSU’s granted during the three months ended September 30, 2015 : Three Months Ended September 30, 2015 Volatility 35.88 % Risk-free interest rate 0.99 % Correlation coefficient 0.25 % Dividend yield - % The Company used historical volatility to calculate the expected volatility for each grant as of the grant date . Historical volatility was determined by calculating the mean reversion of the daily adjusted closing stock price. The risk-free interest rate assumption is based upon observed U.S. Treasury bill interest rates (risk-free) appropriate for the term of the Company’s stock options and Market Condition RSU’s. The expected holding period of stock options represents the period of time options are expec ted to be outstanding and is based on historical experience. The vesting period ranges from one to four years and the contractual life is ten years. The correlation coefficient, used to value the Market Condition RSU’s, represents the way in which entities move in relation to the Russell 3000 index as a whole. Stock- based c ompensation expense related to stock options, restricted stock units , Market Condition RSU’s and the ESPP for the three and nine months ended September 30, 2015 and 2014 was allocated as follows: Three Months Ended Nine Months Ended September 30, September 30, 2015 2014 2015 2014 (in thousands) Cost of revenues $ 18 $ 36 $ 54 $ 94 Sales and marketing 149 100 343 244 General and administrative 583 463 1,580 1,160 Research and development 27 16 72 36 Total stock-based compensation $ 777 $ 615 $ 2,049 $ 1,534 On April 28, 2015, the Company announced the appointment of James Green to its Board of Directors and the retirement of Robert Dishman from its Board of Directors . As part of Dr. Dishman’s retirement, the Company ( i ) awarded an unrestricted stock award to Dr. Dishman on April 28, 2015, having an aggregate cash value of $80,000, (ii) accelerated the vesting of all outstanding stock options and restricted stock units that were unvested as of April 28, 2015, and (iii) e xtended the post-retirement option exercise period for each option to the earlier to occur of the respective scheduled expiration date or April 28, 2016. Total compensation expense recognized as part of general and administrative expenses for the nine months ended September 30, 2015 , as part of these modifications, was approximately $0.1 million. The Company did not capitalize any stock-based compensation. Earnings per share Basic earnings per share is based upon net income divided by the number of weighted average common shares outstanding during the period. The calculation of diluted earnings per share assumes conversion of stock options, restricted stock units and Market Condition RSU’s into common stock using the treasury method. The weighted av erage number of shares used to compute basic and diluted earnings per share consists of the following: Three Months Ended Nine Months Ended September 30, September 30, 2015 2014 2015 2014 Basic 33,933,327 32,341,586 33,473,958 32,079,744 Effect of assumed conversion of employee and director stock options and restricted stock units - 1,073,271 - 1,017,268 Diluted 33,933,327 33,414,857 33,473,958 33,097,012 Excluded from the shares used in calculating the diluted earnings per common share in the above table are options, restricted stock units and Market Condition RSU’s of approximately 5,640,536 and 2,449,873 shares of common stock for the three months ended September 30, 2015 and 2014 , respectively, as the impact of these shares would be anti-dilutive. Excluded from the shares used in calculating the diluted earnings per common share in the above table are options, restricted sto ck units and Market Condition RSU’s of approximately 5,640,536 and 2,535,314 shares of common stock for the nine months ended September 30, 2015 and 2014 , respectively, as the impact of these shares would be anti-diluti ve.

Long Term Debt

Long Term Debt	9 Months Ended
Long Term Debt	Sep. 30, 2015
Long Term Debt Disclosure [Abstract]
Long Term Debt Disclosure [Text Block]	14. Long Term Debt On August 7, 2009, the Company entered into an Amended and Restated Revolving Credit Loan Agreement related to a $20.0 million revolving credit facility with Bank of America, as agent, and Bank of America and Brown Brothers Harriman & Co as lenders (as amended, the “2009 Credit Agreement”) . On September 30, 2011, the Company entered into the First Amendment to the Amended and Restated Revolving Credit Loan Agreement (the “First Amendment”) with Bank of America as agent, and Bank of America and Brown Brothers Harriman & Co as lenders. The First Amendment extended the maturity date of the credit facility to August 7, 2013 and reduced the interest rate to the London Interbank Offered Rate plus 3.0%. On October 4, 2012, the Company entered into the Second Amendment to the Amen ded and Restated Revolving Credit Loan Agreement (the “Second Amendment”) with Bank of America as agent, and Bank of America and Brown Brothers Harriman & Co as lende rs. The Second Amendment extended the maturity date of the credit facility to August 7, 20 14 . On March 29, 2013, the Company entered into a Second Amended and Restated Revolving Credit Agreement ( as amended, the “Credit Agreement”) with Bank of America, as agent, and Bank of America and Brown Brothers Harriman & Co as lenders , that amended and restated the 2009 Credit Agreement . The Credit Agreement converted the Company’s existing outstanding revolving advances into a term loan in the principal amount of $15.0 million (the “Term Loan”), provides a revolving credit facility in the maximum princ ipal amount of $25.0 million (“Revolving Line”) and provides a delayed draw term loan of up to $15.0 million (the “DDTL”) to fund capital contributions to the Company’s former subsidiary, HART. The maximum amount available under the Credit Agreement is $5 0.0 million as borrowings against the DDTL in excess of $10.0 million results in a dollar for dollar reduction in the Revolving Line capacity. The Revolving Line, Term Loan and DDTL each have a maturity date of March 29, 2018 (the maturity date of the Revo lving Line was extended from March 29, 2016 in connection with the Third Amendment discussed below ). On October 31, 2013, the Company amended the Credit Agreement to reduce the DDTL from up to $15.0 million to up to $10. 0 million and allow for an additional $5.0 million to be available for drawing as advances under the Revolving Line. On April 24, 2015, the Company entered into the Third Amendment to the Second Amended and Restated Credit Agreement (the “Third Amendment” ). The Third Amendment extended the maturity date of the Revolving Line to March 29, 2018 and reduced the interest rates on the Revolving Line, Term Loan and DDTL. B orrowings under the Term Loan and the DDTL accrued interest at a rate based on either the effective London Interbank Offered Rate (LIBOR) for certain interest periods selected by the Company, or a daily floating rate based on the British Bankers’ Association (BBA) LIBOR as published by Reuters (or other commercially available source providing q uotations of BBA LIBOR), plus in either case, a margin of 2.75 %. Additionally, t he Revolving Line accrued interest at a rate based on either the effective LIBOR for certain interest periods selected by the Company, or a daily floating rate based on the BBA LIBOR, plus in either case, a margin of 2. 25 %. The Company was required to fix the rate of interest on at least 50% of the Term Loan and the DDTL through the purchase of interest rate swaps. The Term Loan and DDTL each have interest payments due at the e nd of the applicable LIBOR period, or monthly with respect to BBA LIBOR borrowings, and principal payments due quarterly. The Revolving Line has interest payments due at the end of the applicable LIBOR period, or monthly with respect to BBA LIBOR borrowing s. On June 30, 2015, the Company entered into the Fourth Amendment to the Second Amended and Restated Credit Agreement (the “Fourth Amendment”), which amended the Company’s quarterly minimum fixed charge coverage financial covenant. The loans evidenced by the Credit Agreement, or the Loans, are guaranteed by all of the Company’s direct and indirect domestic subsidiaries, and secured by substantially all of the assets of the Company and the guarantors. The Loans are subject to res trictive covenants under the Credit Agreement, and financial covenants that require the Company and its subsidiaries to maintain certain financial ratios on a consolidated basis, including a maximum leverage, minimum fixed charge coverage and minimum worki ng capital. Prepayment of the Loans is allowed by the Credit Agreement at any time during the terms of the Loans. The Loans also contain limitations on the Company’s ability to incur additional indebtedness and requires lender approval for acquisitions fun ded with cash, promissory notes and/or other consideration in excess of $6.0 million and for acquisitions funded solely with equity in excess of $10.0 million. As of September 30, 2015 and December 31, 2014 , the C ompany had borrowings of $ 20.2 million and $ 21.5 million, respectively, outstanding under its Credit Agreement. As of September 30, 2015 , the Company was in compliance with all financial covenants contained in the Credit A greement, was subject to covenant and w orking capital borr owing restriction s and had available borrowing capacity under its Credit Agreement of $ 5.6 million. As of September 30, 2015 , the weighted effective interest rates on the Company’s Term Loan, DDTL and Revolving Line borrowings were 3.96% , 3.44% and 2.44% , respectively. As of September 30, 2015 and December 31, 2014 , the Company’s borrowings were comprised of: September 30, December 31, 2015 2014 (in thousands) Long-term debt: Term loan $ 7,500 $ 9,750 DDTL 6,000 7,500 Revolving line 6,650 4,200 Total debt 20,150 21,450 Less: current installments (5,000) (5,000) Long-term debt $ 15,150 $ 16,450

Derivatives

Derivatives	9 Months Ended
Derivatives	Sep. 30, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities Disclosure [Text Block]	15 . Derivatives The Company uses interest -rate -related derivative instruments to manage its exposure related to changes in interest rates on its variable -rate debt instruments. The Company does not enter into derivative instruments for any purpose other than cash flow hedging. The Company does not speculate using derivative instruments. By using derivative financial instruments to hedge exposures to changes in interest rates, the Company exposes itself to credit risk and market risk. Credit risk is the f ailure of the counterparty to perform under the terms of the derivative contract. When the fair value of a derivative contract is positive, the counterparty owes the Company, which creates credit risk for the Company. When the fair value of a derivative co ntract is negative, the Company owes the counterparty and, therefore, the Company is not exposed to the counterparty’s credit risk in those circumstances. The Company minimizes counterparty credit risk in derivative instruments by entering into transaction s with carefully selected major financial institutions based upon their credit profile. Market risk is the adverse effect on the value of a derivative instrument that results from a change in interest rates. The market risk associated with interest -rat e contracts is managed by establishing and monitoring parameters that limit the types and degree of market risk that may be undertaken. The Company assesses interest rate risk by continually identifying and monitoring changes in interest rate exposures th at may adversely impact expected future cash flows and by evaluating hedging opportunities. The Company maintains risk management control systems to monitor interest rate risk attributable to both the Company’s outstanding or forecasted debt obligations as well as the Company’s offsetting hedge positions. The risk management control systems involve the use of analytical techniques, including cash flow sensitivity analysis, to estimate the expected impact of changes in interest rates on the Company’s future cash flows. The Company uses variable -rate London Interbank Offered Rate (LIBOR) debt to finance its operations. The debt obligations expose the Company to variability in interest payments due to changes in interest rates. Management believes that it is p rudent to limit the variability of a portion of its interest payments. To meet this objective, management enters into LIBOR based interest rate swap agreements to manage fluctuations in cash flows resulting from changes in the benchmark interest rate of LI BOR. These swaps change the variable -rate cash flow exposure on the debt obligations to fixed cash flows. Under the terms of the interest rate swaps, the Company receives LIBOR based variable interest rate payments and makes fixed interest rate payments, thereby creating the equivalent of fixed-rate debt for the notional amount of its debt hedged. In accordance with its Credit Agreement, the Company was required to fix the rate of interest on at least 50% of its Term Loan and the DDTL through the purchase of interest rate swaps. On June 5, 2013, the Company entered into an interest rate swap contract with an original notional amount of $15.0 million and a maturity date of March 29, 2018 in order to hedge the risk of changes in the effective benchmark inter est rate (LIBOR) associated with the Company’s Term Loan. On November 29, 2013, the Company entered into a second interest rate swap contract with an original notional amount of $5.0 million and a maturity date of March 29, 2018 in order to hedge the risk of changes in the effective benchmark interest rate (LIBOR) associated with the DDTL. The notional amount of the Company’s derivative instruments as of September 30, 2015 was $10.5 million . The Term Loan swap contract effectively converted specific variable-ra te debt into fixed-rate debt and fixed the LIBOR rate associated with the Term Loan at 0.96% plus a ba nk margin of 3.0% . The DDTL swap contract effectively converted specific variable-rate debt into fixed-rate debt and fixed the LIBOR rate a ssociated with the Term Loan at 0.93% plus a bank margin of 3.0% .The interest rate swap s were designated as cash flow hedge s in accordance with ASC 815, Derivatives and Hedging . The following table presents the notional amo unt and fair value of the Company ’ s derivative instrument s as of September 30, 2015 and December 31, 2014 . September 30, 2015 September 30, 2015 Notional Amount Fair Value (a) Derivatives designated as hedging instruments under ASC 815 Balance sheet classification (in thousands) Interest rate swaps Other liabilities-non current $ 10,500 $ (56) December 31, 2014 December 31, 2014 Notional Amount Fair Value (a) Derivatives designated as hedging instruments under ASC 815 Balance sheet classification (in thousands) Interest rate swaps Other liabilities-non current $ 13,500 $ (18) (a) See Note 16 for the fair value measurements related to these financial instruments. All of the Company’s derivative instruments are designated as hedging instruments. The Company has structured its interest rate swap agreements to be 100% effective and as a result, there was no impact to earnings resulting from hedge ineffectiveness. Changes in the fair value of interest rate swaps designated as hedging instruments that effectively offset the variability of cash flows associate d with variable -rate, long -term debt obligations are reported in accumulated other comprehensive income (“AOCI”). These amounts subsequently are reclassified into interest expense as a yield adjustment of the hedged interest payments in the same period in which the related interest affects earnings. The Company’s interest rate swap agreement was deemed to be fully effective in accordance with ASC 815, and, as such, unrealized gains and losses related to these derivatives were recorded as AOCI. The followin g table summarizes the e ffect of derivatives designated as cash flow hedging instruments and their classification within comprehensive loss for the three and nine months ended September 30, 2015 and 2014 : Derivatives in Hedging Relationships Amount of gain or (loss) recognized in OCI on derivative (effective portion) Three Months Ended Nine Months Ended September 30, September 30, 2015 2014 2015 2014 (in thousands) Interest rate swaps $ (39) $ 23 $ (110) $ (57) The following table summarizes the reclassifications out of accumulated other comprehensive loss for the three and nine months ended September 30, 2015 and 2014 : Details about AOCI Components Amount reclassified from AOCI into income (effective portion) Location of amount Three Months Ended Nine Months Ended reclassified from September 30, September 30, AOCI into income 2015 2014 2015 2014 (effective portion) (in thousands) Interest rate swaps $ 22 $ 31 $ 72 $ 100 Interest expense As of September 30, 2015 , $ 0.1 million of deferred losses on derivative instruments accumulated in AOCI are expected to be reclassified to earnings during the next twelve months. Transactions and events expected to occur over the next twelve months that will necessitate reclassifying these derivatives’ losses to earnings include the repricing of variable -rate debt. There were no cash flow hedges discontinued during 2015 or 2014 .

Fair Value Measurements

Fair Value Measurements	9 Months Ended
Fair Value Measurements	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	16 . Fair Value Measurements Fair value measurement is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy is established, which prioritizes the inputs used in measuring fair value into three broad levels as follows: Level 1—Quoted prices in active markets for identical assets or liabi lities. Level 2—Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. Level 3—Unobservable inputs based on the Company’s own assumptions. The following table s present the fair value hierarchy for those liabilities measured at fair value on a recurring basis: Fair Value as of September 30, 2015 (In thousands) Level 1 Level 2 Level 3 Total Liabilities: Interest rate swap agreements $ - $ 56 $ - $ 56 Fair Value as of December 31, 2014 (In thousands) Level 1 Level 2 Level 3 Total Liabilities: Interest rate swap agreements $ - $ 18 $ - $ 18 The Company uses the market approach technique to value its financial liabilities. The Company’s financial liabilities carried at fair value include derivative instruments used to hedge the Company’s interest rate risks. The fair value of the Company’s interest rate swap agreement s was based on LIBOR yield curves at the reporting date.

Income Taxes

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2015
Income Tax [Abstract]
Income Taxes Disclosure [Text Block]	17. Income Tax Income tax was an approximately $ 0.2 million benefit and $ 0.3 million expense for the three months ended September 30, 2015 and 2014 , respectively. The increased tax benefit for the three months ended September 30, 2015 reflects the incremental benefit recorded for the nine months ended September 30, 2015 associated with actual results for the nine-month period, as described below. The effective income tax rate was 33.8% for the three months ended September 30, 2014 . Discrete items included in the tax benefit for the three months ended September 30, 2015 included non-deductible acquisition costs and a return to provision adjustment . Tax expense for the three months ended September 30, 2014 inc luded a discrete item for non-deductible acquisition costs. Income tax was an approximately $ 1.4 million benefit and $ 0.9 million expense for the nine months ended September 30, 2015 and 2014 , respectively. The effective incom e tax rate was 42.3% for the nine months ended September 30, 2015 , compared with 26.8% for the same period in 2014 . The tax benefit for the nine months ended September 30, 2015 was based on the actual results for the nine -month period rather than an effective tax rate estimated for the entire year. The Company continues to utilize a year-to-date approach to provide a better estimate of income tax expense based on its revised 2015 forecast of pre-tax income, mix of incom e across jurisdictions, as well as the impact of permanent differences on its revised forecast of pre-tax income. The difference between the Company’s effective tax rate year over year was primarily attributable to the use of a year-to-date approach at September 30, 2015 , the impact of increased research and development tax incentives and incentive stock option exercises on lower pre-tax earnings in 2015 as well as the mix of earnings between its domestic and foreign businesses and a return to provisio n adjustment, partially offset by non- deductible acquisition costs incurred versus 2014.

Subsequent Events

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	1 8. Subsequent Events The Company committed to a restructuring plan on October 27, 2015, which includes eliminating certain positions made redundant as a result of its site consolidations, as well as a realignment of our commercial sales team. The restructuring plan is expected to be completed on or before December 31, 2015. In connection with the plan, Harvard Bioscience expects to record a restructuring charge during the fourth quarter of 2015 of approximately $0.4 million, on a pre-tax basis. O n November 5 , 2015, the Company entered into an agreement with its lenders which eliminated the Company’s 2015 fourth quarter minimum fixed charge coverage financial covenant requirement. As part of the agreement, the maximum principal amount on the Revol ving Line was reduced to $10.0 million until June 30, 2016, at which time, the maximum principal amount will be restored to $25.0 million, as long as the Company remains in compliance with all covenants.

Summary of Significant Accounti

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2015
Recently Issued Accounting Pronouncements [Abstract]
Recently Issued Accounting Pronouncements Disclosure [Text Block]	2 . Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, “Revenue from Contracts with Customers,” a new accounting standard that provides for a comprehensive model to use in the accounting for revenue arising from contracts with customers that will replace most existing revenue recognition guidance in U.S. GAAP. Under this standard, revenue will be re cognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. At its July 2015 meeting, the FASB agreed to defer the mandatory effective date of ASU 2014-09 one year. Under the one year deferral, the standard will take effect in 2018 for calendar year-end public entities. The Company is assessing the new standard and has not yet determined the impact to the consolida ted financial statements. In April 2015, the FASB issued ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs . The update requires debt issuance costs related to a recognized debt liabili ty to be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability, instead of being presented as an asset. Debt disclosures will include the face amount of the debt liability and the effective interest rat e. The update requires retrospective application and represents a change in accounting principle. The update is effective for fiscal years beginning after December 15, 2015. Early adoption is permitted for financial statements that have not been previousl y issued. The Company is evaluating the impact of ASU 2015-03 on its consolidated financial statements and the possibility of early adoption by the Company. In July 2015, the FASB issued ASU 2015-11, Simplifying Measurement of Inventory . The update requir es measurement of most inventory “at the lower of cost and net realizable value”, and applies to all entities that recognize inventory within the scope of ASC 330, except for inventory measured under the last-in, first-out (LIFO) method or the retail inven tory method (RIM). ASU 2015-11 requires prospective application and represents a change in accounting principle. The update is effective for fiscal years beginning after December 15, 2016. Early adoption is permitted for financial statements that have not been previously issued. The Company is evaluating the impact of ASU 2015-11 on its consolidated financial statements and the possibility of early adoption by the Company. In September 2015, the FASB issued ASU 2015-16, Simplifying the Accounting for Meas urement-Period Adjustments . The update eliminates the requirement to retrospectively adjust financial statements for measurement-period adjustments that occur in periods after a business combination. Under the update, measurement-period adjustments are to be calculated as if they were known at the acquisition date, but are recognized in the reporting period in which they are determined. Additional disclosures are required about the impact on current-period earnings. ASU 2015-16 requires prospective applicat ion to adjustments of provisional amounts that occur after the effective date. The update is effective for fiscal years beginning after December 15, 2016. Early adoption is permitted for financial statements that have not been previously issued. The Compa ny is evaluating the impact of ASU 2015-16 on its consolidated financial statements and the possibility of early adoption by the Company.

Accumulated Other Comprehensi25

Accumulated Other Comprehensive Income (Tables)	9 Months Ended
Accumulated Other Comprehensive Income (Tables)	Sep. 30, 2015
Accumulated Other Comprehensive Income [Abstract]
Accumulated Other Comprehensive Income [Table Text Block]	Foreign currency Derivatives translation qualifying as Defined benefit (in thousands) adjustments hedges pension plans Total Balance at December 31, 2014 $ (4,658) $ (18) $ (3,557) $ (8,233) Other comprehensive loss before reclassifications (3,263) (110) - (3,373) Amounts reclassified from AOCI - 72 - 72 Other comprehensive loss (3,263) (38) - (3,301) Balance at September 30, 2015 $ (7,921) $ (56) $ (3,557) $ (11,534)
Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]	Details about AOCI Components Amount reclassified from AOCI into income (effective portion) Location of amount Three Months Ended Nine Months Ended reclassified from September 30, September 30, AOCI into income 2015 2014 2015 2014 (effective portion) (in thousands) Interest rate swaps $ 22 $ 31 $ 72 $ 100 Interest expense

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
Acquisitions (Tables)	Sep. 30, 2015
Acquisition Disclosure [Abstract]
Schedule of Business Acquisitions [Table Text Block]	(in thousands) Tangible assets $ 4,165 Liabilities assumed (2,819) Net assets 1,346 Goodwill and intangible assets: Goodwill 2,061 Trade name 774 Customer relationships 1,627 Developed technology 1,338 Non-compete agreements 27 Deferred tax liabilities (1,245) Total goodwill and intangible assets, net of tax 4,582 Acquisition purchase price $ 5,928 Three Months Ended Nine Months Ended September 30, 2014 September 30, 2014 (in thousands) Pro Forma Revenues $ 26,829 $ 82,441 Net income 707 2,597 (in thousands) Tangible assets $ 5,442 Liabilities assumed (1,207) Net assets 4,235 Goodwill and intangible assets: Goodwill 3,745 Trade name 1,008 Customer relationships 1,204 Developed technology 2,452 Non-compete agreements 148 Deferred tax liabilities (1,603) Total goodwill and intangible assets, net of tax 6,954 Acquisition purchase price $ 11,189 Three Months Ended Nine Months Ended September 30, 2014 September 30, 2014 (in thousands) Pro Forma Revenues $ 27,209 $ 83,702 Net income 713 2,619 (in thousands) Tangible assets $ 1,278 Liabilities assumed (530) Net assets 748 Goodwill and intangible assets: Goodwill 946 Trade name 143 Customer relationships 308 Developed technology 363 Non-compete agreements 30 Deferred tax liabilities (325) Total goodwill and intangible assets, net of tax 1,465 Acquisition purchase price $ 2,213

Goodwill and Other Intangible27

Goodwill and Other Intangible Assets (Tables)	9 Months Ended
Goodwill and Other Intangible Assets (Tables)	Sep. 30, 2015
Goodwill And Other Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets and Goodwill [Table Text Block]	Weighted Average September 30, 2015 December 31, 2014 Life (a) (in thousands) Amortizable intangible assets: Gross Accumulated Amortization Gross Accumulated Amortization Existing technology $ 16,287 $ (11,620) $ 15,538 $ (11,198) 7.5 Years Trade names 7,685 (2,954) 7,114 (2,557) 9.2 Years Distribution agreements/customer relationships 23,818 (11,568) 22,730 (10,681) 10.2 Years Patents 250 (85) 256 (49) 3.4 Years Total amortizable intangible assets 48,040 $ (26,227) 45,638 $ (24,485) Indefinite-lived intangible assets: Goodwill 40,858 39,822 Other indefinite-lived intangible assets 1,231 1,252 Total goodwill and other indefinite-lived intangible assets 42,089 41,074 Total intangible assets $ 90,129 $ 86,712 (a) Weighted average life as of September 30, 2015.
Goodwill Rollforward [Table Text Block]	(in thousands) Balance at December 31, 2014 $ 39,822 Goodwill arising from business combinations 2,061 Effect of change in currency translation (1,025) Balance at September 30, 2015 $ 40,858

Inventories (Tables)

Inventories (Tables)	9 Months Ended
Inventories (Tables)	Sep. 30, 2015
Inventories Disclosure [Abstract]
Schedule of Inventory [Table Text Block]	September 30, December 31, 2015 2014 (in thousands) Finished goods $ 10,169 $ 10,138 Work in process 949 946 Raw materials 11,893 9,447 Total $ 23,011 $ 20,531

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	9 Months Ended
Property, Plant and Equipment (Tables)	Sep. 30, 2015
Property, Plant and Equipment Disclosure [Abstract]
Schedule Of Property Plant And Equipment [Table Text Block]	September 30, December 31, 2015 2014 (in thousands) Land, buildings and leasehold improvements $ 2,635 $ 2,595 Machinery and equipment 10,129 10,102 Computer equipment and software 7,356 6,322 Furniture and fixtures 1,353 1,125 Automobiles 106 56 21,579 20,200 Less: accumulated depreciation (15,645) (15,010) Property, plant and equipment, net $ 5,934 $ 5,190

Restructuring and Other Exit 30

Restructuring and Other Exit Costs (Tables)	9 Months Ended
Restructuring and Other Exit Costs (Tables)	Sep. 30, 2015
Restructuring and Related Activities [Abstract]
Restructuring Plan Table [Table Text Block]	Severance Costs (in thousands) Restructuring charges $ 14 Cash payments (14) Restructuring balance at September 30, 2015 $ - Severance Costs Other Total (in thousands) Restructuring charges $ 126 46 $ 172 Non-cash reversal of restructuring charges (6) - (6) Cash payments (59) (32) (91) Restructuring balance at September 30, 2015 $ 61 14 $ 75 Severance Costs Other Total (in thousands) Restructuring balance at December 31, 2014 $ 626 $ - $ 626 Restructuring charges 87 293 380 Non-cash reversal of restructuring charges (73) - (73) Cash payments (577) (263) (840) Effect of change in currency translation (8) - (8) Restructuring balance at September 30, 2015 $ 55 $ 30 $ 85 Severance and Fixed Asset Related Costs Write Offs Other Total (in thousands) Restructuring balance at December 31, 2013 $ 1,434 $ - $ - $ 1,434 Restructuring charges 199 13 257 469 Non-cash reversal of restructuring charges (117) (13) - (130) Cash payments (1,447) - (234) (1,681) Restructuring balance at September 30, 2014 $ 69 $ - $ 23 $ 92 Severance and Related Costs (in thousands) Restructuring balance at December 31, 2013 $ 3 Non-cash reversal of restructuring charges (3) Restructuring balance at September 30, 2014 $ - Three Months Ended Nine Months Ended September 30, September 30, 2015 2014 2015 2014 (in thousands) Restructuring charges $ 376 $ 97 $ 487 $ 349

Warranties (Tables)

Warranties (Tables)	9 Months Ended
Warranties (Tables)	Sep. 30, 2015
Warranties Disclosure [Abstract]
Warranty Rollforward Disclosure [Table Text Block]	Beginning Additions/ Ending Balance Payments (Credits) Balance (in thousands) Year ended December 31, 2014 $ 305 (102) 49 $ 252 Nine months ended September 30, 2015 $ 252 (73) (33) $ 146

Employee Benefit Plans (Tables)

Employee Benefit Plans (Tables)	9 Months Ended
Employee Benefit Plans (Tables)	Sep. 30, 2015
Employee Benefit Plans Disclosure [Abstract]
Schedule of Changes in Projected Benefit Obligations [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2015 2014 2015 2014 (in thousands) Components of net periodic benefit cost: Interest cost 175 200 542 649 Expected return on plan assets (165) (147) (510) (478) Net amortization loss 75 40 231 131 Net periodic benefit cost $ 85 $ 93 $ 263 $ 302

Leases (Tables)

Leases (Tables)	9 Months Ended
Leases (Tables)	Sep. 30, 2015
Leases Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Operating Leases (in thousands) 2016 $ 1,803 2017 1,705 2018 1,688 2019 1,490 2020 1,490 Thereafter 4,508 Net minimum lease payments $ 12,684

Capital Stock (Tables)

Capital Stock (Tables)	9 Months Ended
Capital Stock (Tables)	Sep. 30, 2015
Capital Stock Disclosure [Abstract]
Schedule Of Stock Options And Restricted Stock Units Activity Rollforward [Table Text Block]	Stock Options Restricted Stock Units Market Condition RSU's Weighted Stock Average Restricted Market Options Exercise Stock Units Grant Date Condition RSU's Grant Date Outstanding Price Outstanding Fair Value Outstanding Fair Value Balance at December 31, 2014 6,263,112 $ 3.42 306,397 $ 4.30 - $ - Granted 868,000 5.51 254,685 5.56 196,785 4.81 Exercised (1,739,134) 3.04 - - - - Vested (RSUs) - - (237,188) - - - Cancelled / forfeited (272,121) 3.98 - - - - Balance at September 30, 2015 5,119,857 $ 3.87 323,894 $ 5.30 196,785 $ 4.81
Table Of Assumptions [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2015 2014 2015 2014 Volatility 39.47 % 56.96 % 41.07 % 56.83 % Risk-free interest rate 1.76 % 1.90 % 1.72 % 1.79 % Expected holding period (in years) 5.25 years 5.93 years 5.52 years 5.75 years Dividend yield - % - % - % - % Three Months Ended September 30, 2015 Volatility 35.88 % Risk-free interest rate 0.99 % Correlation coefficient 0.25 % Dividend yield - %
Stock Based Compensation Expense Activity By Function [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2015 2014 2015 2014 (in thousands) Cost of revenues $ 18 $ 36 $ 54 $ 94 Sales and marketing 149 100 343 244 General and administrative 583 463 1,580 1,160 Research and development 27 16 72 36 Total stock-based compensation $ 777 $ 615 $ 2,049 $ 1,534
Basic and Diluted Shares [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2015 2014 2015 2014 Basic 33,933,327 32,341,586 33,473,958 32,079,744 Effect of assumed conversion of employee and director stock options and restricted stock units - 1,073,271 - 1,017,268 Diluted 33,933,327 33,414,857 33,473,958 33,097,012

Long Term Debt (Tables)

Long Term Debt (Tables)	9 Months Ended
Long Term Debt (Tables)	Sep. 30, 2015
Long Term Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]	September 30, December 31, 2015 2014 (in thousands) Long-term debt: Term loan $ 7,500 $ 9,750 DDTL 6,000 7,500 Revolving line 6,650 4,200 Total debt 20,150 21,450 Less: current installments (5,000) (5,000) Long-term debt $ 15,150 $ 16,450

Derivative (Tables)

Derivative (Tables)	9 Months Ended
Derivative (Tables)	Sep. 30, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]	September 30, 2015 September 30, 2015 Notional Amount Fair Value (a) Derivatives designated as hedging instruments under ASC 815 Balance sheet classification (in thousands) Interest rate swaps Other liabilities-non current $ 10,500 $ (56) December 31, 2014 December 31, 2014 Notional Amount Fair Value (a) Derivatives designated as hedging instruments under ASC 815 Balance sheet classification (in thousands) Interest rate swaps Other liabilities-non current $ 13,500 $ (18) (a) See Note 16 for the fair value measurements related to these financial instruments.
Schedule of Cash Flow Hedges Included in AOCI [Table Text Block]	Derivatives in Hedging Relationships Amount of gain or (loss) recognized in OCI on derivative (effective portion) Three Months Ended Nine Months Ended September 30, September 30, 2015 2014 2015 2014 (in thousands) Interest rate swaps $ (39) $ 23 $ (110) $ (57)
Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]	Details about AOCI Components Amount reclassified from AOCI into income (effective portion) Location of amount Three Months Ended Nine Months Ended reclassified from September 30, September 30, AOCI into income 2015 2014 2015 2014 (effective portion) (in thousands) Interest rate swaps $ 22 $ 31 $ 72 $ 100 Interest expense

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
Fair Value Measurements (Tables)	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis [Table Text Block]	Fair Value as of September 30, 2015 (In thousands) Level 1 Level 2 Level 3 Total Liabilities: Interest rate swap agreements $ - $ 56 $ - $ 56 Fair Value as of December 31, 2014 (In thousands) Level 1 Level 2 Level 3 Total Liabilities: Interest rate swap agreements $ - $ 18 $ - $ 18

Accumulated Other Comprehensi38

Accumulated Other Comprehensive Income (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Opening Balance	$ (8,233)
Other Comprehensive Income (Loss) before Reclassifications	(3,373)
Reclassification from Accumulated Other Comprehensive Income	72
Other Comprehensive Income (Loss), Net of Tax, total	(3,301)
Closing Balance	(11,534)
Foreign currency translation adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Opening Balance	(4,658)
Other Comprehensive Income (Loss) before Reclassifications	(3,263)
Reclassification from Accumulated Other Comprehensive Income	0
Other Comprehensive Income (Loss), Net of Tax, total	(3,263)
Closing Balance	(7,921)
Derivatives qualifying as hedges [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Opening Balance	(18)
Other Comprehensive Income (Loss) before Reclassifications	(110)
Reclassification from Accumulated Other Comprehensive Income	72
Other Comprehensive Income (Loss), Net of Tax, total	(38)
Closing Balance	(56)
Defined benefit pension plans [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Opening Balance	(3,557)
Other Comprehensive Income (Loss) before Reclassifications	0
Reclassification from Accumulated Other Comprehensive Income	0
Other Comprehensive Income (Loss), Net of Tax, total	0
Closing Balance	$ (3,557)

Accumulated Other Comprehensi39

Accumulated Other Comprehensive Income (Details 1) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Reclassifications Out of Accumulated Other Comprehensive Income [Line Items]
Derivatives Reclassification Adjustment from AOCI, net tax	$ (22)	$ (31)	$ (72)	$ (100)
Reclassification from Accumulated Other Comprehensive Income			$ (72)

Acquisitions (Narratives) (Deta

Acquisitions (Narratives) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Acquisitions (Narratives) (Details) - USD ($) $ in Millions	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Business Acquisition [Line Items]
Business Acquisition Direct Acquisition Costs In Income Statement	$ 0.2	$ 0.3	$ 0.9	$ 0.4

Acquisitions (Details 1)

Acquisitions (Details 1) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
Acquisitions (Details 1) - USD ($) $ in Thousands	Sep. 30, 2014	Sep. 30, 2014	Jan. 08, 2015	Oct. 02, 2014
Multi Channel Systems MCS GmbH [Member]
Business Acquisition [Line Items]
Tangible Assets Acquired				$ 5,442
Liabilities Assumed				(1,207)
Net Tangible Assets Acquired				4,235
Business Acquisition Purchase Price Allocation Intangible Assets [Abstract]
Purchase Price Allocation, Goodwill Amount				3,745
Deferred Tax Liabilities				1,603
Business Acquisition Purchase Price Allocation Total Intangible Assets Amount Including Goodwill				6,954
Total Acquisition Purchase Price				11,189
Business Acquisition, Cost of Acquired Entity 1 [Abstract]
Business Acquisition Cost Of Acquired Entity Purchase Price 1				11,189
Business Acquisitions Pro Forma Revenue	$ 27,209	$ 83,702
Business Acquisitions Pro Forma Net Income Loss	713	2,619
Multi Channel Systems MCS GmbH [Member] \| Unpatented Technology [Member]
Business Acquisition Purchase Price Allocation Intangible Assets [Abstract]
Purchase Price Allocation, Amortizable Intangible Assets				2,452
Multi Channel Systems MCS GmbH [Member] \| Customer Relationships [Member]
Business Acquisition Purchase Price Allocation Intangible Assets [Abstract]
Purchase Price Allocation, Amortizable Intangible Assets				1,204
Multi Channel Systems MCS GmbH [Member] \| Trade Names [Member]
Business Acquisition Purchase Price Allocation Intangible Assets [Abstract]
Purchase Price Allocation, Amortizable Intangible Assets				1,008
Multi Channel Systems MCS GmbH [Member] \| Non compete Agreements [Member]
Business Acquisition Purchase Price Allocation Intangible Assets [Abstract]
Purchase Price Allocation, Amortizable Intangible Assets				148
Triangle BioSystems, Inc. [Member]
Business Acquisition [Line Items]
Tangible Assets Acquired				1,278
Liabilities Assumed				(530)
Net Tangible Assets Acquired				748
Business Acquisition Purchase Price Allocation Intangible Assets [Abstract]
Purchase Price Allocation, Goodwill Amount				946
Deferred Tax Liabilities				325
Business Acquisition Purchase Price Allocation Total Intangible Assets Amount Including Goodwill				1,465
Total Acquisition Purchase Price				2,213
Business Acquisition, Cost of Acquired Entity 1 [Abstract]
Business Acquisition Cost Of Acquired Entity Purchase Price 1				2,213
Triangle BioSystems, Inc. [Member] \| Customer Relationships [Member]
Business Acquisition Purchase Price Allocation Intangible Assets [Abstract]
Purchase Price Allocation, Amortizable Intangible Assets				308
Triangle BioSystems, Inc. [Member] \| Trade Names [Member]
Business Acquisition Purchase Price Allocation Intangible Assets [Abstract]
Purchase Price Allocation, Amortizable Intangible Assets				143
Triangle BioSystems, Inc. [Member] \| Patented Technology [Member]
Business Acquisition Purchase Price Allocation Intangible Assets [Abstract]
Purchase Price Allocation, Amortizable Intangible Assets				363
Triangle BioSystems, Inc. [Member] \| Non compete Agreements [Member]
Business Acquisition Purchase Price Allocation Intangible Assets [Abstract]
Purchase Price Allocation, Amortizable Intangible Assets				$ 30
HEKA Elektronik [Member]
Business Acquisition [Line Items]
Tangible Assets Acquired			$ 4,165
Liabilities Assumed			2,819
Net Tangible Assets Acquired			1,346
Business Acquisition Purchase Price Allocation Intangible Assets [Abstract]
Purchase Price Allocation, Goodwill Amount			2,061
Deferred Tax Liabilities			1,245
Business Acquisition Purchase Price Allocation Total Intangible Assets Amount Including Goodwill			4,582
Total Acquisition Purchase Price			5,928
Business Acquisition, Cost of Acquired Entity 1 [Abstract]
Business Acquisition Cost Of Acquired Entity Purchase Price 1			5,928
Business Acquisitions Pro Forma Revenue	26,829	82,441
Business Acquisitions Pro Forma Net Income Loss	$ 707	$ 2,597
HEKA Elektronik [Member] \| Unpatented Technology [Member]
Business Acquisition Purchase Price Allocation Intangible Assets [Abstract]
Purchase Price Allocation, Amortizable Intangible Assets			1,338
HEKA Elektronik [Member] \| Customer Relationships [Member]
Business Acquisition Purchase Price Allocation Intangible Assets [Abstract]
Purchase Price Allocation, Amortizable Intangible Assets			1,627
HEKA Elektronik [Member] \| Trade Names [Member]
Business Acquisition Purchase Price Allocation Intangible Assets [Abstract]
Purchase Price Allocation, Amortizable Intangible Assets			774
HEKA Elektronik [Member] \| Non compete Agreements [Member]
Business Acquisition Purchase Price Allocation Intangible Assets [Abstract]
Purchase Price Allocation, Amortizable Intangible Assets			$ 27

Goodwill and Other Intangible42

Goodwill and Other Intangible Assets (Narratives) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Goodwill And Other Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 666	$ 618	$ 2,137	$ 1,839
Estimated Amortization Expense Next Twelve Months	2,800		2,800
Estimated Amortization Expense Year 2	2,800		2,800
Estimated Amortization Expense Year 3	2,500		2,500
Estimated Amortization Expense Year 4	2,300		2,300
Estimated Amortization Expense Year 5	$ 2,200		$ 2,200

Goodwill and Other Intangible43

Goodwill and Other Intangible Assets (Details 1) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 48,040	$ 45,638
Finite-Lived Intangible Assets, Accumulated Amortization	(26,227)	(24,485)
Goodwill	40,858	39,822
Other indefinite lived intangible assets	1,231	1,252
Total goodwill and other indefinite lived intangible assets	42,089	41,074
Total intangible assets	90,129	86,712
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	16,287	15,538
Finite-Lived Intangible Assets, Accumulated Amortization	$ (11,620)	(11,198)
Finite-Lived Intangible Assets, Weighted Average Useful Life	7 years 6 months
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 7,685	7,114
Finite-Lived Intangible Assets, Accumulated Amortization	$ (2,954)	(2,557)
Finite-Lived Intangible Assets, Weighted Average Useful Life	9 years 2 months 12 days
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 23,818	22,730
Finite-Lived Intangible Assets, Accumulated Amortization	$ (11,568)	(10,681)
Finite-Lived Intangible Assets, Weighted Average Useful Life	10 years 2 months 12 days
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 250	256
Finite-Lived Intangible Assets, Accumulated Amortization	$ (85)	$ (49)
Finite-Lived Intangible Assets, Weighted Average Useful Life	3 years 4 months 24 days

Goodwill and Other Intangible44

Goodwill and Other Intangible Assets (Details 2) $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Goodwill And Other Intangible Assets Disclosure [Abstract]
Goodwill, Beginning Balance	$ 39,822
Acquired during the period	2,061
Foreign currency translation adjustments related to goodwill balance	(1,025)
Goodwill, Ending Balance	$ 40,858

Inventories (Details 1)

Inventories (Details 1) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Inventories Disclosure [Abstract]
Finished Goods	$ 10,169	$ 10,138
Work in Process	949	946
Raw Materials	11,893	9,447
Total Inventories, Net	$ 23,011	$ 20,531

Property, Plant and Equipment46

Property, Plant and Equipment (Details 1) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 21,579	$ 20,200
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	(15,645)	(15,010)
Property, plant and equipment, net	5,934	5,190
Land, Buildings and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	2,635	2,595
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	10,129	10,102
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	7,356	6,322
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	1,353	1,125
Automobiles [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 106	$ 56

Restructuring and Other Exit 47

Restructuring and Other Exit Cots (Narratives) (Details) - USD ($) $ in Thousands	Oct. 27, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Restructuring Cost and Reserve [Line Items]
Restructuring charges (credits)		$ 376	$ 97	$ 487	$ 349
Restructuring Plan December 2013 [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges (credits)					469
Restructuring number of positions eliminated, percent		13.00%		13.00%
Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges (credits)	$ 400
Employee Severance [Member] \| Restructuring Plan December 2013 [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges (credits)					199
Other Costs [Member] \| Restructuring Plan December 2013 [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges (credits)					$ 257

Restructuring and Other Exit 48

Restructuring and Other Exit Costs (Details 1) - USD ($) $ in Thousands	Oct. 27, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Restructuring Reserve [Roll Forward]
Restructuring charges (credits)		$ 376	$ 97	$ 487	$ 349
Restructuring Plan December 2013 [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance					1,434
Restructuring charges (credits)					469
Restructuring Reserve, Settled with Cash					(1,681)
Restructuring Reserve, Accrual Adjustment					(130)
Restructuring Reserve, Ending Balance			92		92
Restructuring Plan 2014 [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance				626
Restructuring charges (credits)				380
Restructuring Reserve, Settled with Cash				(840)
Restructuring Reserve, Accrual Adjustment				(73)
Restructuring Reserve, Ending Balance		85		85
Restructuring Reserve, Translation Adjustment				(8)
Restructuring Plan Q1 2015 [Member]
Restructuring Reserve [Roll Forward]
Restructuring charges (credits)				172
Restructuring Reserve, Settled with Cash				(91)
Restructuring Reserve, Accrual Adjustment				(6)
Restructuring Reserve, Ending Balance		75		75
Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring charges (credits)	$ 400
Employee Severance [Member] \| Restructuring Plan 2012 [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance					3
Restructuring Reserve, Accrual Adjustment					(3)
Restructuring Reserve, Ending Balance			0		0
Employee Severance [Member] \| Restructuring Plan December 2013 [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance					1,434
Restructuring charges (credits)					199
Restructuring Reserve, Settled with Cash					(1,447)
Restructuring Reserve, Accrual Adjustment					(117)
Restructuring Reserve, Ending Balance			$ 69		69
Employee Severance [Member] \| Restructuring Plan 2014 [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance				626
Restructuring charges (credits)				87
Restructuring Reserve, Settled with Cash				(577)
Restructuring Reserve, Accrual Adjustment				(73)
Restructuring Reserve, Ending Balance		55		55
Restructuring Reserve, Translation Adjustment				(8)
Employee Severance [Member] \| Restructuring Plan Q1 2015 [Member]
Restructuring Reserve [Roll Forward]
Restructuring charges (credits)				126
Restructuring Reserve, Settled with Cash				(59)
Restructuring Reserve, Accrual Adjustment				(6)
Restructuring Reserve, Ending Balance		61		61
Employee Severance [Member] \| Restructuring Plan Q2 2015 [Member]
Restructuring Reserve [Roll Forward]
Restructuring charges (credits)				14
Restructuring Reserve, Settled with Cash				(14)
Restructuring Reserve, Ending Balance		0		0
Other Costs [Member] \| Restructuring Plan December 2013 [Member]
Restructuring Reserve [Roll Forward]
Restructuring charges (credits)					257
Restructuring Reserve, Settled with Cash					(234)
Restructuring Reserve, Accrual Adjustment					0
Other Costs [Member] \| Restructuring Plan 2014 [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance					$ 0
Restructuring charges (credits)				293
Restructuring Reserve, Settled with Cash				(263)
Restructuring Reserve, Accrual Adjustment				0
Restructuring Reserve, Ending Balance		30		30
Restructuring Reserve, Translation Adjustment				0
Other Costs [Member] \| Restructuring Plan Q1 2015 [Member]
Restructuring Reserve [Roll Forward]
Restructuring charges (credits)				46
Restructuring Reserve, Settled with Cash				(32)
Restructuring Reserve, Accrual Adjustment				0
Restructuring Reserve, Ending Balance		$ 14		$ 14

Related Party Transactions (Nar

Related Party Transactions (Narratives) (Details) - USD ($)	3 Months Ended		9 Months Ended
Related Party Transactions (Narratives) (Details) - USD ($)	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Business Acquisition [Line Items]
Operating Leases, Rent Expense, Net	$ 600,000	$ 300,000	$ 1,800,000	$ 1,100,000
Multi Channel Systems MCS GmbH [Member]
Business Acquisition [Line Items]
Operating Leases, Rent Expense, Net	59,000		172,000
Triangle BioSystems, Inc. [Member]
Business Acquisition [Line Items]
Operating Leases, Rent Expense, Net	$ 11,000		$ 32,000

Warranties (Details 1)

Warranties (Details 1) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
Warranties (Details 1) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Product Warranty Disclosure [Abstract]
Warranty, Beginning Balance	$ 252	$ 305
Warranty payments	(73)	(102)
Warranty additions	(33)	49
Warranty, Ending Balance	$ 146	$ 252

Employee Benefit Plans (Narrati

Employee Benefit Plans (Narratives) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Employee Benefit Plans Disclosure [Abstract]
Expected employer contribution in current remaining fiscal year			$ 200
Fair Value Impairment Of Pension Assets		$ 600
Defined Benefit Plan Payments In Current Fiscal Year	$ 200	200	600	$ 600
Defined Benefit Plans Liabilities Noncurrent	4,500		4,500		$ 4,400
Unrealized losses on pension benefit obligation, net of tax	$ 0	$ 0	$ 0	$ 484

Employee Benefit Plans (Details

Employee Benefit Plans (Details 1) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Employee Benefit Plans (Details 1) - USD ($) $ in Thousands	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Employee Benefit Plans Disclosure [Abstract]
Interest Cost	$ 175	$ 200	$ 542	$ 649
Expected Return on Plan Assets	(165)	(147)	(510)	(478)
Net Amortization Loss	75	40	231	131
Net Periodic Benefit Cost, Total	85	93	263	302
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Interest Cost	175	200	542	649
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Defined Benefit Plan Payments In Current Fiscal Year	$ 200	$ 200	$ 600	$ 600

Leases (Narratives) (Details)

Leases (Narratives) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Leases (Narratives) (Details) - USD ($) $ in Millions	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Leases Disclosure [Abstract]
Estimated Rental Expenses Current Year			$ 2.2
Operating Leases, Rent Expense, Net	$ 0.6	$ 0.3	$ 1.8	$ 1.1

Leases (Details 1)

Leases (Details 1) $ in Thousands	Sep. 30, 2015USD ($)
Leases Disclosure [Abstract]
2,016	$ 1,803
2,017	1,705
2,018	1,688
2,019	1,490
2,020	1,490
Thereafter	4,508
Operating Leases, Total Future Minimum Payments Due	$ 12,684

Capital Stock (Narratives) (Det

Capital Stock (Narratives) (Details) - USD ($)	Apr. 28, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Apr. 03, 2015	Dec. 31, 2014
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date				85.00%
Employee Stock Purchase Plan Shares Authorized		750,000		750,000		750,000
Stock issued during the year, Shares, Employee Stock Purchase Plans				26,181	31,116	611,369
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized							17,508,929
Increase In Number Of Shares Authorized For Issuance Under Stock Option And Incentive Plan							2,500,000
Equity Instruments Other than Options, Grants in Period				254,685
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		5,640,536	2,449,873	5,640,536	2,535,314
Percentage Of Outstanding Common Stock		20.00%		20.00%		20.00%
Weighted Average Estimated Black Scholes Value Of Option Grants		$ 2.14	$ 2.64	$ 2.21	$ 2.2
Preferred Stock - Shares Authorized		5,000,000		5,000,000		5,000,000		5,000,000
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 80,000
Accelerated Share Based Compensation Expense	$ 100,000
Market Condition Restricted Stock Unit [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Equity Instruments Other than Options, Grants in Period				196,785

Capital Stock (Details 1)

Capital Stock (Details 1) - $ / shares	3 Months Ended		9 Months Ended
Capital Stock (Details 1) - $ / shares	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Apr. 03, 2015	Dec. 31, 2014
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Opening Balance Stock Options Outstanding			6,263,112
Begining Balance Weighted Average Exercise Price			$ 3.42
Increase In Number Of Shares Authorized For Issuance Under Stock Option And Incentive Plan					2,500,000
Options, Grants in Period, Gross			868,000
Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 5.51
Options, Forfeitures and Expirations in Period			(272,121)
Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price			$ 3.98
Closing Balance Stock Options Outstanding	5,119,857		5,119,857
Closing Balance Weighted Average Exercise Price	$ 3.87		$ 3.87
Begining Balance Restricted Stock Units Outstanding			306,397
Equity Instruments Other than Options, Grants in Period			254,685
Equity Instruments Other than Options, Vested in Period			(237,188)
Closing Balance Restricted Stock Units Outstanding	323,894		323,894
Begining Balance Grant Date Fair Value Of Restricted Stock Units			$ 4.3
Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value			5.56
Closing Balance Grant Date Fair Value Of Restricted Stock Units	$ 5.3		$ 5.3
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Fair Value Assumptions, Expected Volatility Rate	39.47%	56.96%	41.07%	56.83%
Fair Value Assumptions, Risk Free Interest Rate	1.76%	1.90%	1.72%	1.79%
Fair Value Assumptions, Expected Term	5 years 3 months	5 years 11 months 4 days	5 years 6 months 7 days	5 years 9 months
Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%	0.00%	0.00%
Options, Exercises in Period, Weighted Average Exercise Price			$ 3.04
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Grant Date Fair Value			$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period			0
Preferred Stock - Shares Authorized	5,000,000		5,000,000			5,000,000
Stock Issued During Period Gross Stock Options Exercised			1,739,134
Market Condition Restricted Stock Unit [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Equity Instruments Other than Options, Grants in Period			196,785
Equity Instruments Other than Options, Vested in Period			0
Closing Balance Restricted Stock Units Outstanding	196,785		196,785
Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 4.81
Closing Balance Grant Date Fair Value Of Restricted Stock Units	$ 4.81		$ 4.81
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Fair Value Assumptions, Expected Volatility Rate	35.88%
Fair Value Assumptions, Risk Free Interest Rate	0.99%
Fair Value Assumptions, Expected Dividend Rate	0.00%
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Correlation Coefficient	0.25%
Stock Options And Restricted Stock Units Cancelled			0

Capital Stock (Details 2)

Capital Stock (Details 2) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Capital Stock (Details 2) - USD ($) $ in Thousands	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	$ 777	$ 615	$ 2,049	$ 1,534
Weighted Average Number Diluted Shares Outstanding Adjustment [Abstract]
Basic	33,933,327	32,341,586	33,473,958	32,079,744
Weighted Average Number Diluted Shares Outstanding Adjustment	0	1,073,271	0	1,017,268
Diluted	33,933,327	33,414,857	33,473,958	33,097,012
Cost of Sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	$ 18	$ 36	$ 54	$ 94
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	27	16	72	36
Selling and Marketing Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	149	100	343	244
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	$ 583	$ 463	$ 1,580	$ 1,160

Capital Stock (Details 3)

Capital Stock (Details 3) - shares	Sep. 30, 2015	Dec. 31, 2014
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	5,119,857	6,263,112

Long Term Debt (Narratives) (De

Long Term Debt (Narratives) (Details) - USD ($) $ in Thousands	Apr. 24, 2015	Oct. 31, 2013	Mar. 29, 2013	Aug. 07, 2009	Sep. 30, 2015	Dec. 31, 2014
Credit Agreement [Line Items]
Previous Approved Credit Facility				$ 20,000
Secured Debt					$ 20,150	$ 21,450
Line of Credit Facility, Maximum Borrowing Capacity			$ 50,000
Minimum percentage of Term Loan and the DDTL that company was required to fix the rate of interest on					50.00%	50.00%
Line of Credit Facility, Remaining Borrowing Capacity					$ 5,600
Interest Rate In Excess Of LIBOR On Credit Facility				3.00%
DDTL Threshold For Dollar For Dollar Reduction In Revolving Line			10,000
Transfer Of Delayed Draw Down Term Loan Capacity To Revolver Capacity		$ 5,000
Lender Approval To Fund Acquisition With Cash Promissory Note In Excess Of Threshold					6,000
Lender Approval To Fund Acquisition With Equity In Excess Of Threshold					10,000
Revolving Credit Facility [Member]
Credit Agreement [Line Items]
Secured Debt			$ 25,000		$ 6,650	$ 4,200
Maturity Dates			Mar. 29, 2016
Basis Spread Over LIBOR	2.25%
Interest Rate As Of Reporting Date					2.44%
Term Loan [Member]
Credit Agreement [Line Items]
Secured Debt			$ 15,000		$ 7,500	9,750
Maturity Dates			Mar. 29, 2018
Basis Spread Over LIBOR	2.75%
Interest Rate As Of Reporting Date					3.96%
Delayed Drawdown Term Loan [Member]
Credit Agreement [Line Items]
Secured Debt			$ 15,000		$ 6,000	$ 7,500
Maturity Dates			Mar. 29, 2018
Basis Spread Over LIBOR	2.75%
Maximum Borrowings Available Under The Current Credit Agreement		$ 10,000
Interest Rate As Of Reporting Date					3.44%

Long Term Debt (Details 1)

Long Term Debt (Details 1) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014	Mar. 29, 2013
Debt Instrument [Line Items]
Secured Debt	$ 20,150	$ 21,450
Current portion, long-term debt	(5,000)	(5,000)
Long-term debt	15,150	16,450
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Secured Debt	6,650	4,200	$ 25,000
Term Loan [Member]
Debt Instrument [Line Items]
Secured Debt	7,500	9,750	15,000
Delayed Drawdown Term Loan [Member]
Debt Instrument [Line Items]
Secured Debt	$ 6,000	$ 7,500	$ 15,000

Derivative (Narratives) (Detail

Derivative (Narratives) (Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
Derivative (Narratives) (Details) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014	Nov. 30, 2013	Jun. 05, 2013
Derivative Instruments And Hedging Activities Disclosure [Line Items]
Minimum percentage of Term Loan and the DDTL that company was required to fix the rate of interest on	50.00%	50.00%
Deferred losses on derivative instruments accumulated in AOCI expected to be reclassified to earnings	$ 0.1
Derivative Interest Rate Swap Effective Percentage	100.00%
Delayed Drawdown Term Loan [Member]
Derivative Instruments And Hedging Activities Disclosure [Line Items]
Notional Amount of Interest Rate Swaps			$ 5
LIBOR Fixed Rate	0.93%
Term Loan [Member]
Derivative Instruments And Hedging Activities Disclosure [Line Items]
Notional Amount of Interest Rate Swaps				$ 15
LIBOR Fixed Rate	0.96%

Derivative (Details 1)

Derivative (Details 1) - Other liabilities-non current [Member] - Derivatives qualifying as hedges [Member] - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Derivatives, Fair Value [Line Items]
Notional Amount of Interest Rate Derivatives	$ 10,500	$ 13,500
Derivative Liability, Fair Value, Net	$ (56)	$ (18)

Derivative (Details 2)

Derivative (Details 2) - Derivatives qualifying as hedges [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Loss Recognized in Other Comprehensive Income (Loss), Effective Portion	$ (39)	$ 23	$ (110)	$ (57)
Interest Expense [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Loss Reclassified from Accumulated OCI into Income, Effective Portion	$ 22	$ 31	$ 72	$ 100

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Derivatives qualifying as hedges [Member] - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative Liabilities	$ 56	$ 18
Fair Value, Inputs, Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative Liabilities	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative Liabilities	56	18
Fair Value, Inputs, Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative Liabilities	$ 0	$ 0

Income Tax (Narratives) (Detail

Income Tax (Narratives) (Details)	3 Months Ended	9 Months Ended
Income Tax (Narratives) (Details)	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Tax [Abstract]
Effective Income Tax Rate	33.80%	42.30%	26.80%

Subsequent Events (Narratives)

Subsequent Events (Narratives) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Nov. 05, 2015	Dec. 31, 2014
Subsequent Event [Line Items]
Restructuring charges (credits)	$ 376	$ 97	$ 487	$ 349
Secured Debt	$ 20,150		$ 20,150			$ 21,450
Revolving Credit Facility [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Secured Debt					$ 25,000
Temporary Reduced Credit Line					$ 10,000